Patient Derived Xenograft/PDX Models

World Market Report

MCP13873

EXECUTIVE ENGAGEMENTS

POOL

463
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

93
Interactions with Platform & by Email

PARTICIPANTS

19
Unique # Participated

VALIDATIONS

8
Responses Validated*

COMPANIES

38
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2022

TABLES

123

PAGES

192

EDITION

7

PRICE

USD 4950

CODE

MCP13873


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

STRONG ACTIVE NICHE TRIVIAL

%

VALIDATED RESEARCH *

S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

Global Patient Derived Xenograft/PDX Models Market to Reach $255.5 Million by 2026

Amid the COVID-19 crisis, the global market for Patient Derived Xenograft/PDX Models estimated at US$102.7 Million in the year 2020, is projected to reach a revised size of US$255.5 Million by 2026, growing at a CAGR of 16.3% over the analysis period. Mouse, one of the segments analyzed in the report, is projected to record a 15.3% CAGR and reach US$197.3 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Rat segment is readjusted to a revised 18.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $36.1 Million in 2021, While China is Forecast to Reach $44.8 Million by 2026

The Patient Derived Xenograft/PDX Models market in the U.S. is estimated at US$36.1 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$44.8 Million by the year 2026 trailing a CAGR of 15.7% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.5% and 14% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.9% CAGR.

SELECT PLAYERS

Champions Oncology, Inc.; Charles River Laboratories International, Inc.; Crown Bioscience, Inc.; Epo Berlin-Buch GmbH; Hera BioLabs; Oncodesign; Pharmatest Services Ltd.; The Jackson Laboratory; Urolead SAS; WuXi AppTec; Xentech

SEGMENTS

» Application (Pre-Clinical Drug Development, Basic Cancer Research) » End-Use (Pharma & Biotech, CRO) » Type (Mouse, Rat)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
World Current & Future Analysis for Mouse by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Mouse by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Rat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Rat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Pre-Clinical Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Pre-Clinical Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Basic Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Basic Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for Pharma & Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Pharma & Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
World Current & Future Analysis for CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
CANADA
Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
JAPAN
Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
CHINA
China Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
China Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
China Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
China 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
EUROPE
Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
FRANCE
France Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
France Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
France Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
France 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
GERMANY
Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
ITALY
Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
Total Companies Profiled: 38

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com